# Clinical Sensitivity and Interpretation of PCR and Serological

# **2 COVID-19 Diagnostics for Patients Presenting to the Hospital**

- 3 Tyler E. Miller, M.D., Ph.D.<sup>1\*</sup>, Wilfredo F. Garcia Beltran, M.D., Ph.D.<sup>1\*</sup>, Adam Z. Bard, MBA,
- 4 MSF<sup>1\*</sup>, Tasos Gogakos, M.D., Ph.D. <sup>1\*</sup>, Melis N. Anahtar, M.D., Ph.D. <sup>1</sup>, Michael Gerino
- 5 Astudillo, M.D. <sup>1</sup>, Diane Yang, Ph.D. <sup>1</sup>, Julia Thierauf, Ph.D. <sup>1</sup>, Adam S. Fisch, M.D., Ph.D. <sup>1</sup>,
- 6 Grace K. Mahowald, M.D., Ph.D. 1, Megan J. Fitzpatrick, M.D. 1, Valentina Nardi, M.D. 1, Jared
- Feldman<sup>3</sup>, Blake M. Hauser<sup>3</sup>, Timothy M. Caradonna<sup>3</sup>, Hetal D. Marble, Ph.D. <sup>1</sup>, Lauren L.
- 8 Ritterhouse, M.D., Ph.D. <sup>1</sup>, Sara E. Turbett, M.D. <sup>1,2</sup>, Julie Batten, MLS (ASCP) <sup>1</sup>, Nicholas
- 9 Zeke Georgantas<sup>1</sup>, Galit Alter, Ph.D.<sup>3</sup>, Aaron G. Schmidt, Ph.D.<sup>3</sup>, Jason B. Harris, M.D.<sup>4</sup>, Jeffrey
- 10 A. Gelfand, M.D.<sup>2</sup>, Mark C. Poznansky, M.D., Ph.D.<sup>2</sup>, Bradley E. Bernstein, M.D., Ph.D.<sup>1</sup>,
- David N. Louis, M.D.<sup>1</sup>, Anand Dighe, M.D., Ph.D.<sup>1</sup>, Richelle C. Charles, M.D.<sup>2</sup>, Edward T.
- Ryan, M.D. <sup>2</sup>, John A. Branda, M.D. <sup>1</sup>, Virginia M. Pierce, M.D. <sup>1,4</sup>, Mandakolathur R. Murali,
- 13 M.D. <sup>1,5</sup>, A. John Iafrate, M.D., Ph.D. <sup>1</sup>, Eric S. Rosenberg, M.D. <sup>1,2</sup>, Jochen Lennerz, M.D.,
- 14 Ph.D.<sup>1</sup>\*\*

24

26

29

3031

1

- 15 1. Department of Pathology, Massachusetts General Hospital/Harvard Medical School,
- 16 Boston, MA, USA
- 2. Division of Infectious Diseases, Department of Medicine, Massachusetts General
- Hospital/Harvard Medical School, Boston, MA, USA
- 19 3. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
- 4. Division of Infectious Diseases, Department of Pediatrics, Massachusetts General
- 21 Hospital/Harvard Medical School, Boston, MA, USA
- 5. Division of Allergy and Immunology, Department of Medicine, Massachusetts General
- Hospital/Harvard Medical School, Boston, MA, USA
- \*These authors contributed equally
- 27 \*\* Correspondence should be addressed to Jochen Lennerz, M.D., Ph.D. at
- 28 jlennerz@partners.org

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

**Abstract (n=248 of 250) Introduction:** The diagnosis of COVID-19 requires integration of clinical and laboratory data. SARS-CoV-2 diagnostic assays play a central role in diagnosis and have fixed technical performance metrics. Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges. Our goal was to examine the clinical sensitivity of two most common SARS-CoV-2 diagnostic test modalities, polymerase chain reaction (PCR) and serology, over the disease course to provide insight into their clinical interpretation in patients presenting to the hospital. **Methods:** A single-center, retrospective study. To derive clinical sensitivity of PCR, we identified 209 PCR-positive SARS-CoV-2 patients with multiple PCR test results (624 total PCR tests) and calculated daily sensitivity from date of symptom onset or first positive test. To calculate daily clinical sensitivity by serology, we utilized 157 PCRpositive patients with a total of 197 specimens tested by enzyme-linked immunosorbent assay for IgM, IgG, and IgA anti-SARS-CoV-2 antibodies. **Results:** Clinical sensitivity of PCR decreased with days post symptom onset with >90% clinical sensitivity during the first 5 days after symptom onset, 70-71% from days 9-11, and 30% at day 21. In contrast, serological sensitivity increased with days post symptom onset with >50% of patients seropositive by at least one antibody isotype after day 7, >80% after day 12, and 100% by day 21. Conclusion: PCR and serology are complimentary modalities that require timedependent interpretation. Superimposition of sensitivities over time indicate that serology can function as a reliable diagnostic aid indicating recent or prior infection.

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Introduction While many measures to mitigate the multifactorial impact of COVID-19 are being implemented, one critical component of this strategy is the widespread testing and identification of individuals currently or previously infected by SARS-CoV-2. The delivery of effective care and mitigation of infection centers around the performance of SARS-CoV-2 diagnostic testing and the clinical interpretation of results. The lack of a full understanding of the natural history and immunopathogenesis of COVID-19 infection creates unique challenges in the implementation of diagnostic testing strategies. SARS-CoV-2 diagnostic assays have fixed technical performance metrics (e.g., sensitivity and specificity). Clinical sensitivity depends on more than technical performance and is also a function of pre-analytical variables and the disease state of the patient. Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges. The goal of this study is to examine the clinical sensitivity and provide insights into the interpretation of the two most common SARS-CoV-2 diagnostic test modalities: PCR and serology. Laboratory-based diagnosis of active SARS-CoV-2 infection relies on the direct detection of virus-specific nucleic acids, most commonly obtained from the nasopharynx of infected patients. Indirect markers of infection include the detection of SARS-CoV-2 specific antibodies, generated as part of the human immune response to the virus. Serologic testing holds promise as a blood-based diagnostic aid, as a marker of viral exposure, and potentially as an indicator of protective immunity. Understanding the presence of these biomarker in relationship to one another and over the natural course of infection is required to effectively utilize these available diagnostic tests in clinical practice (1-3). Here, we share our experience of SARS-CoV-2 PCR sensitivity and separately obtained IgM, IgA, and IgG sensitivity of an in-house enzyme-linked immunosorbent assay (ELISA) during the natural course of disease in a cohort of patients presenting to the hospital.

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

Methods **Setting and Design.** The study was designed as a single-center, retrospective review of PCR results and serology data. PCR results were obtained between 3/3/2020 and 4/15/2020 and we superimposed serology data obtained from confirmed COVID-19 positive patients as part of ongoing clinical validation studies of an enzyme-linked immunosorbent assay (ELISA) for regulatory approval. The study was conducted with approval from the local Institutional Review Board. **PCR.** Nucleic acid testing was performed as part of clinical care using three emergencyuse authorized real-time PCR assays. Our laboratory-developed real-time PCR assay uses the Centers for Disease Control and Prevention primers targeting regions of the N gene of SARS-CoV-22, the cobas SARS-CoV-2 Test performed on the cobas 6800 targets regions of the ORF1a and E genes, and the Xpert Xpress SARS-CoV-2 assay run on the GeneXpert Infinity targets regions of the N and E genes. The choice of testing platform was determined by access to reagents available at the time of clinical testing provided for patient care (see supplement). **Serology.** An in-house enzyme-linked immunosorbent assay was used to measure IgG, IgA, and IgM antibodies that target the SARS-CoV-2 receptor binding domain (RBD) within the spike protein. The assay has been validated within MGH clinical laboratories as a high-complexity molecular test (see supplement). Patient cohorts and statistical analysis. An initial PCR-query was performed to delineate clinical sensitivity over time, and analysis was restricted to patients with multiple PCR test results and at least one positive. These patients were considered confirmed COVID-19 positive and taken as true positives. In this subset, 83% were inpatients, 13% were patients from the ED, and 4% were outpatients. We calculated daily clinical sensitivity rates by dividing positive tests by all tests at each day post symptom onset and after first positive PCR-test. To estimate the time when PCR sensitivity reaches zero, we modeled a linear daily regression trend after first positive PCR-test (see supplement).

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Serologic analysis of IgM, IgA and IgG status was performed in a subset of all SARS-CoV-2 PCR-positive patients and for each sample, we determined the days post symptom onset at the collection date and calculated daily sensitivity for each antibody isotype as well as sensitivity of any isotype. We plotted the sensitivity for both test modalities as percentages per overlapping 5-day leading intervals against the days since symptom onset (see supplement). Results PCR sensitivity for SARS-CoV-2 nucleic acid decreased with days post symptom onset SARS-CoV-2 viral RNA levels decline over the course of infection(4). This decline of RNA levels clearly impacts the clinical sensitivity of PCR testing. It is not possible to determine the false negative rate of the PCR test from patients with a single PCR result. Therefore, we identified patients with multiple PCR tests who had at least one positive test result (considered true positives). The resulting dataset is composed of 624 test results from 209 patients (6.6% of all PCR-positive patients, Table 1). We compared this subset to all tested patients (Supplemental Figure 1, Supplemental Table 1) and contingency analysis of the multi-PCR vs. all single PCR-positive patient subset showed no significant differences in age, gender, and test type (Supplemental Table 1, Supplemental Figure 2). Thus, we consider the multi-PCR subset is demographically representative of our tested patient population. To derive clinical sensitivity over disease course, we needed to define an anchor point. We chose two different anchor points: symptom onset (subjective) and first positive test (objective). First, we examined the time-course by anchoring test results to the day of symptom onset (Figure 1, Supplemental Figure 3). Clinical sensitivity remains above 90% for the first 5 days after symptom onset. In our cohort of patients presenting to the hospital, patients were admitted to the hospital a median of 8 days after symptom onset (interquartile range: 4-16 days; mean: 10 days), and between days 6-8, the clinical sensitivity of PCR ranged from 84-76%. On subsequent days the sensitivity decreases, and at day 18 the sensitivity decreases below 50%. We also compared sensitivity data from an earlier study of mildly symptomatic patients(4) and noted a steeper PCR

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

sensitivity decline, consistent with viral levels dropping more quickly in this population (Supplemental Figure 4). This data provides sensitivity estimates at the time of presentation (e.g., a patient presents at day 10 after symptom onset). Second, we also modeled how PCR sensitivity decreases over time after the first positive PCR-test (Supplemental Figure 3 and Supplemental Figure 5). Regression modeling and extension of PCR-positivity decay (foot-point analysis) revealed that in our cohort, NP-swab specimens could stay PCR-positive beyond 20 and up to 40 days (Supplemental Figure 5). Serological assay sensitivity increases with days post symptom onset Seroconversion is also a dynamic response to the virus and assay sensitivity changes over time. To assess the sensitivity of our serology assay over time, we tested for IgM, IgG, and IgA antibodies against the receptor binding domain (RBD) of SARS-CoV-2 spike protein in a 157 SARS-CoV-2 PCR-positive patients using an in-house ELISA (Table 1). For some patients, we were able to assess serology at multiple time points (n=591 total isotype tests on 197 total specimens). Anchoring our serologic results to days after symptom onset shows that seroconversion starts as early as symptom onset, is detectable in 50% of subjects after day 7, and continues to increase with >80% of patients showing seropositivity after day 12 (Table 2, Figure 1, Supplemental Figure 4, Supplemental Table 2). In the subset of patients with multiple serological tests we saw isotype switching occur as short as 1-4 days, consistent with recent reports(5). Of note, we detected IgA prior to IgM or IgG in a number of individuals, with 2 subjects having only detectable IgA within 3 days of symptom onset. We also documented cases of IgG positivity prior to IgM or IgA, highlighting the utility of measuring seroconversion using all 3 isotypes (Supplemental Table 3, Supplemental Figure 6). The superimposition of serologic sensitivities with PCR sensitivities shows that, after day 7, seroconversion is a reliable diagnostic aid indicating recent or prior infection (Figure 1).

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

**Discussion** We present the dynamic clinical sensitivity of SARS-CoV-2 PCR and our serology platform in patients presenting to the hospital. We performed this single-center, retrospective analysis to share early real-world evidence that can inform interpretation of PCR and serologic testing. We focused on assessing the clinical utility of both modalities in conjunction by direct superimposition of both sensitivity time courses. The direct superimposition shows that serology can function as a reliable diagnostic aid indicating recent or prior infection – in particular at times when PCR sensitivity is lower than 70%. Our findings emphasize that understanding the specific sensitivity kinetics of both modalities is paramount for interpretation and effective utilization of SARS-CoV-2 diagnostics. There is considerable interest in moving SARS-CoV-2 diagnostics to evidence-based principles (6-9). While clinicians await formal guidance from large, prospective, multicenter studies – which will be challenging during the ongoing pandemic – there is considerable uncertainty surrounding SARS-CoV-2 diagnostics in clinical practice (3, 10-13). Using available published data (3-7, 12, 14) and data presented here from our hospital, we offer the following five diagnostic principles for consideration: (1) In symptomatic patients, all interpretations are anchored on days post symptom **onset.** Understanding performance characteristics of SARS-CoV-2 diagnostics over the course of the infection is key to interpretation of results. We provide two distinct approaches to anchor interpretation over the course of infection: subjective (date of symptom onset) and objective (first PCR positive result). Both approaches are valid and have limitations. For example, the quality of patient histories is variable and in many cases the day of symptom onset is unknown or cannot easily be reconstructed. As a practical suggestion and whenever available, we place the date of symptom onset in the front page of the (electronic) medical record. (2) PCR is the diagnostic gold standard during acute infection. PCR-testing using consensus primers has an estimated specificity of >99% (15). Based on early reports from Wuhan(16) the overall clinical sensitivity is reported around 70%. We found a

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

clinical sensitivity around 95% in the first five days after symptom onset and although PCR is an imperfect standard concurrent IgM/IgA/IgG antibody assessment in the first 5 days post-symptom onset does not significantly aid in rendering a current diagnosis, and at no point during active infection should serology replace PCR for diagnosis. (3) Clinical sensitivity of PCR decreases with days post symptom onset. In clinical practice many symptomatic patients present to medical care after day 1 of symptom onset. Our data show PCR sensitivity decreases with days post-symptom onset (Figure 1) or days post first PCR-positive test result. Notably, some patients may have an initial PCR-negative result at presentation (Supplemental Figure 3). Our data also indicate that severely ill patients (many patients in our cohort) remain PCR-positive for a longer period than mildly ill patients (patients in the Wölfel et al.(4) cohort). Both time and disease severity may be key elements for the interpretation of PCR results. (4) Serological assay sensitivity increases with days post symptom onset. In our cohort and with our assay, clinical sensitivity of serologic testing surpasses that of PCR after days 8-10 post symptom onset. Remarkably, we find seroconversion does not follow the typical kinetics of IgM antibodies followed by class-switched IgG and IgA antibodies. Rather, all appear simultaneously at a cohort level, with IgG or IgA seropositivity preceding IgM responses in some cases. Supporting this are other studies that report overall low IgM responses to SARS-CoV-2 that are often preceded by IgG(14, 17). These data highlight the benefit of measuring all three anti-SARS-CoV-2 antibody isotypes to maximize sensitivity. In the case of SARS-CoV-2, it is unknown for how long IgM, IgA or IgG antibodies remain detectable after infection. It is important to note that a positive serologic result for IgM, IgA and/or IgG does not conclusively indicate that a patient's presenting symptoms are due to a current SARS-CoV-2 infection. (5) Negative results do not completely preclude SARS-CoV-2 infection. Ruling out SARS-CoV-2 infection remains challenging. Supplementing PCR results with serologic assessment can increase sensitivity (serology as a diagnostic aid). However, our data clearly shows that there is a window period (day 6-12 from symptom onset) when clinical sensitivity of PCR and serological assays are below 90%. In a symptomatic patient, if multiple PCR tests are negative and serological results after 8-12 days are also negative, we believe the likelihood of active SARS-CoV-2 infection to be

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

low. Clinical judgement is needed in this situation as there are rare scenarios where PCR negativity may be due to disease at a different anatomic site and/or serologic negativity may be due to an immunocompromised state. Limitations in our study include relatively small numbers, a retrospective design, and selection bias due to the specific setting and testing practice. We evaluated symptomatic, mostly hospitalized patients and we cannot derive recommendations for asymptomatic or mildly symptomatic patients from our data. Due to limited availability of tests and time constraints during an ongoing pandemic, we do not have daily samples. Date of symptom onset is not consistently available, subjective, and affected by recall biases – yet, it represents a useful anchor point for disease time course in symptomatic patients. Notably, the eclipse period ranges from 2-14 days (18-21) and some patients already mounted a serologic response at the time of presentation, which can be taken as an argument for the early y-axis deviation from zero in the serology curve and a confirmation of date of symptom onset as an imperfect marker. We caution that the presented serology data are specific to our ELISA, and we cannot extrapolate to anti-SARS-CoV-2 antibody responses in general. Nonetheless, other publications indicate that the time courses are comparable (14, 17, 22). Our serological studies measured antibodies to the RBD of SARS-CoV-2. We chose this viral antigen because of its specificity to SARS-CoV-2, and because anti-RBD antibodies are typically neutralizing. Plaque reduction neutralization tests are the gold-standard for assessing neutralizing ability (23-26), and ongoing studies are in progress to confirm anti-RBD antibodies are neutralizing in SARS-CoV-2 infection (27). Some commercially available assays measure the more abundant nucleocapsid protein, which may increase sensitivity to detect a serologic response early in the course of infection, therefore shifting the seroconversion curve to the left. However, antibodies to nucleocapsid protein are unlikely to provide protective immunity as nucleocapsid protein is inaccessible to antibodies in an intact virus. Therefore, serology results also likely depend on the specific antigen being employed in testing. Finally, our multi-PCR cohort and serologic patient cohort are largely non-overlapping (n=20/209) PCR-positive patient. To enable additive sensitivity calculations from combined PCR and serology assays, prospective

and systematically obtained repeated parallel PCR and quantitative serologic data will be necessary.

Determining the clinical sensitivity of SARS-CoV-2 diagnostic tests is an area that does not have time to wait for full, exact analysis during an ongoing pandemic. Our real-world data outline the strengths and weaknesses of two SARS-CoV-2 test modalities over the natural course of infection. We hope these data, in conjunction with the 5 diagnostic principles for consideration, can contribute to effective utilization and interpretation of COVID-19 related laboratory data for patient care.

279 Acknowledgments 280 The authors thank all patients and laboratory staff for making this study possible. 281 CR3022 reference sequences, CR3022-IgA and CR3022-IgM isotypes, and ELISA 282 protocols were kindly provided by Stephanie Fischinger, Caroline Atyeo, and Matthew 283 Slein from the laboratory of Dr. Galit Alter (Ragon Institute). We thanks Yael Heher MD 284 for excellent discussions. ELISA protocols were developed and optimized with the 285 laboratory of Dr. Alejandro Balazs (Ragon Institute). This work is also in part supported 286 by NIH (RO1 CA225655) to J.K.L, Centers for Disease Control and Prevention 287 U01CK000490 (E.T.R., R.C.C.), NIGMS training grant T32 GM007753 (B.M.H., 288 T.M.C), NIH R01 AI146779 (A.G.S.) The content is solely the responsibility of the 289 authors and does not necessarily represent the official views of the National Institute of 290 Health or any other organization. 291

#### References

292

293

- 294 1. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic
- 295 Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative
- 296 Review. Ann Intern Med. 2020;172(11):726-34.
- 297 2. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling Early Humoral Response
- to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020.
- 299 3. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2.
- 300 JAMA. 2020.
- Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al.
- Virological assessment of hospitalized patients with COVID-2019. Nature. 2020.
- He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
- shedding and transmissibility of COVID-19. Nat Med. 2020.
- 305 6. Nicola M, O'Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based
- management guideline for the COVID-19 pandemic Review article. Int J Surg.
- 307 2020;77:206-16.
- 7. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19
- diagnosis and management: a comprehensive review. J Intern Med. 2020.
- 310 8. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19:
- Current Issues and Challenges. J Clin Microbiol. 2020;58(6).
- Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. Sci Transl Med.
- 313 2020;12(546).
- 314 10. Bermingham WH, Wilding T, Beck S, Huissoon A. SARS-CoV-2 serology: Test, test,
- test, but interpret with caution! Clin Med (Lond). 2020.
- 316 11. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians.
- 317 Clin Microbiol Infect. 2020.
- 318 12. Pulia MS, O'Brien TP, Hou PC, Schuman A, Sambursky R. Multi-tiered screening and
- diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to
- 320 pandemic. Ann Med. 2020:1-8.
- 321 13. Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for Certainty on Covid-19
- 322 Antibody Tests At What Cost? N Engl J Med. 2020.
- 323 14. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to
- 324 SARS-CoV-2 in patients with COVID-19. Nat Med. 2020.
- 325 15. Lu X 2020; Pageshttps://wwwnc.cdc.gov/eid/article/26/8/20-1246\_article2020.

- 326 16. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in
- 327 Different Types of Clinical Specimens. JAMA. 2020.
- 328 17. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of IgG and IgM antibodies
- against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis.
- 330 2020.
- Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus
- 332 (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro
- 333 Surveill. 2020;25(5).
- 19. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation
- Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed
- Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-82.
- 20. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
- Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med.
- 339 2020;382(13):1199-207.
- 340 21. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al.
- Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus
- Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data.
- 343 J Clin Med. 2020;9(2).
- 22. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-
- 345 CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020.
- 346 23. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al.
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of
- 348 vulnerability. Science. 2020.
- 349 24. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, et al. Identification of a critical neutralization
- determinant of severe acute respiratory syndrome (SARS)-associated coronavirus:
- importance for designing SARS vaccines. Virology. 2005;334(1):74-82.
- 352 25. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent
- 353 SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal
- model. Science. 2020.
- 355 26. Sun Z, Chen C, Li W, Martinez DR, Drelich A, Baek DS, et al. Potent neutralization of
- 356 SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large
- library with a new stable scaffold. MAbs. 2020;12(1):1778435.
- 358 27. Ju B, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.
- 359 bioRxiv 2020.03.21.990770. 2020.

### **Tables**

Table 1. Demographics of cohorts used in analysis.

	PCR Total n (%)	PCR-positive n (%)	PCR Multiple Tests n (%)	Serology n (%)	
Patients	11,698	3,163 (27)	209	157	
Age	11,000	2,100 (27)		10 /	
Median	46	47	$46^{a}$	57ª	
Average	47.0	48.0	48.6	57	
Range	0 to 102	0 to 102	21 to 93	22 to 98	
Gender					
Female	6,411 (55)	1,584 (25)	110 (53) <sup>b</sup>	55 (35) <sup>b</sup>	
Male	5,270 (45)	1,576 (30)	99 (47)	102 (65)	
Other	22 (0.2)	3 (14)	0	0	

PCR-positive is the SARS-CoV-2 PCR-positive subset of the all tested patients (PCR

Total). PCR Multiple Tests is a cohort of patients with multiple PCR test results (and at

least one positive result) used for clinical sensitivity analysis shown in Figure 1.


Serology is an independent subset of PCR-positive patients. <sup>a</sup>, P<0.01 from student t-test;

Table 2. Sensitivity of anti-SARS-CoV-2 serology by isotype, age, gender, and days post symptom onset.

Total specimens tested Days post symptom onset	197 n	%	Male (% male)	Female (% female)	Age < 70 (% < 70)	$Age \ge 70$ $(\% \ge 70)$
< 8 days (total)	60		39	21	34	26
Positive for IgG	9	15%	7 (18)	2 (10)	6 (18)	3 (12)
Positive for IgG or IgM	12	20%	9 (23)	3 (14)	9 (26)	3 (12)
Positive for IgG or IgM or IgA	15	25%	12 (31)	3 (14)	10 (28)	5 (12)
8 to 14 days (total)	85		58	27	70	15
Positive for IgG	45	53%	33 (57)	12 (44)	40 (57)	5 (33)
Positive for IgG or IgM	53	62%	38 (66)	15 (56)	45 (64)	8 (53)
Positive for IgG or IgM or IgA	58	68%	40 (69)	18 (67)	50 (71)	8 (53)
>14 days (total)	52		35	17	47	5
Positive for IgG	46	88%	30 (86)	16 (94)	42 (89)	4 (80)
Positive for IgG or IgM	47	90%	31 (89)	16 (94)	43 (91)	4 (80)
Positive for IgG or IgM or IgA	49	94%	33 (94)	16 (94)	45 (96)	4 (80)

<sup>&</sup>lt;sup>b</sup>, P<0.01 from Fisher's exact test.

### **Figures**



**Figure 1: Sensitivity by assay modality over time.** Blood-based serologic sensitivity in 157 patients superimposed onto NP swab PCR data from 209 patients. Results for all patient samples from initial symptom onset are plotted: PCR – 516, Serology – 588 (196 samples x 3 isotypes). Serology sensitivity is based on detection of IgM, IgG, or IgA. Sample results prior to day 0 were excluded. PCR and serology samples were obtained in largely different patient populations; therefore, sensitivities are not additive. Data is plotted as 5-day moving average against the days since symptom onset. NA: none assessed.